RxDoctor Payments Data

Owais Khawaja, MD

Interventional Cardiology · Upper Sandusky, OHNPI 1639292584

Payments from drug & device makers

$4,956in general payments, 2019–2025

Across 84 payments — averaging $59.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$4K
  • Inari Medical, Inc.$198
  • Novartis$195
  • AstraZeneca$159
  • Pfizer$138
  • Novo Nordisk$124
  • plus $631 from 15 others

What the payments were for

  • Travel & lodging$2,91159%
  • Food & beverage$1,93539%
  • Education$1102%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,956 in reported general payments places this provider in the 45th percentile of 256 interventional cardiology providers in Ohio.

See all interventional cardiology providers in Ohio

Medicare billing

Part B allowed, 2024
$51,081
Medicare patients
680
Services billed
1,491

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban97$94,239
FarxigaDapagliflozin Propanediol100$66,958
XareltoRivaroxaban51$45,607
EntrestoSacubitril/Valsartan47$40,638
MultaqDronedarone Hcl12$15,175
JardianceEmpagliflozin11$11,167
Praluent PenAlirocumab18$8,696
BrilintaTicagrelor21$8,687
Repatha SyringeEvolocumab13$6,088
Ranolazine ErRanolazine113$5,532
Metoprolol Succinate353$3,580
Ezetimibe104$3,219
Atorvastatin Calcium416$2,544
Carvedilol230$1,364
ClopidogrelClopidogrel Bisulfate172$1,192

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$138$94,23997 claims
AstraZenecaFarxiga, Brilinta$159$75,645121 claims
Johnson & JohnsonXarelto$23$45,60751 claims
NovartisEntresto$195$40,63847 claims
Sanofi-aventis U.S. LLCMultaq$34$15,17512 claims
Boehringer IngelheimJardiance$27$11,16711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 256 interventional cardiology providers in Ohio.

Other interventional cardiology in Upper Sandusky

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →